Play all audios:
_Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox._ Hello, everyone. Damian here with news of an averted activist
challenge, biotech on late-night TV, and the latest deal in oncology’s hottest space. BIOMARIN APPEASES AN ACTIVIST Alexander Hardy, the new CEO of BioMarin Pharmaceutical, had an unenviable
introduction to the job. Weeks before his first day, Elliott Management, a famed and formidable activist investor, disclosed a sizable stake in BioMarin, suggesting trouble ahead for a
management team that had yet to get started. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH
ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+.
Subscribe